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RESULTS
LIMITATIONS
 Small sample size and lack of power 
 The true incidence of hyperglycemia could not be determined 
due to significantly lower POC BG monitoring in phase I and 
missed opportunities in phase II
 Not all recommendations accepted by prescriber in phase II 
 Prescriber hesitancy to accept basal-bolus regimen due to risk of 
hypoglycemia  preferred the use of insulin correction scale 
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DISCUSSION & CONCLUSION
 Pharmacist impact increased POC BG monitoring (36% vs. 88%)
 Larger impact noted in non-DM patients where 
monitoring increased from 9% to 83% 
 Pharmacist impact improved glycemic control 
 Hyperglycemia decreased from 74% to 53% 
 Average POC blood glucose levels decreased from 206 to 182 
mg/dL
 The most common risk factors identified were age greater than 
65 years and BMI > 25 kg/m2 
 A total of 48 pharmacy interventions were made, 38 of which 
were accepted for an overall acceptance rate of 79%
 The most prevalent intervention was the addition of 
point-of-care blood glucose monitoring 
 The incidence of hypoglycemia did not differ significantly 
between the two phases
 Future Directions: Propose collaborative agreement to allow 
automatic ordering of POC BG monitoring in patients meeting 
high dose steroid criteria
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BACKGROUND
 Corticosteroid induced hyperglycemia (CIH) occurs in 86% of 
patients
 Corticosteroids increase post-prandial blood glucose (BG) levels 
(highest 1 - 2 hours after meal) and BG levels normalize at night, 
leading to a normal fasting BG in the morning 
 Risk factors for CIH: high or very high doses of steroids, pre-
existing DM, ethnicity, age 65 or older, eGFR < 40 mL/min/1.73 
m2, BMI > 25 kg/m2, concomitant hyperglycemic medications 
 The goal of managing CIH is to achieve BG <180 mg/dL by 
utilizing basal-bolus insulin regimens plus correction scale and 
monitoring every 4-6 hours 
OBJECTIVE
 To evaluate pharmacist impact on serial blood glucose testing 
and corresponding treatment in patients experiencing CIH in 
the acute inpatient setting
METHODS
 Single center, IRB-approved, two-phased study 
 Phase I: Retrospective chart review (July-September 2018)
 Phase II: Prospective interventional review (February-April 2019) 
 Inclusion criteria: age > 18, admitted to medical surgical floor, 
receiving high or very high dose of systemic corticosteroid for > 
24 hours 
 Exclusion criteria: Diabetic on insulin therapy with average daily 
blood glucose <180 mg/dL, chronic high or very high dose 
corticosteroid use with average daily BG of <180 mg/dL
 Primary outcomes: Percentage of serial BG monitoring, incidence 
of hyperglycemia, average point-of-care (POC) BG levels 
 Secondary outcomes: Risk factors, # of pharmacy interventions 
accepted in phase II
Hyperglycemia = at least one POC BG > 180 mg/dL within 24 hours
• > 100 mg prednisone equivalent per dayVery high dose 
• > 30 mg prednisone equivalent per dayHigh dose 
• > 7.5 mg prednisone equivalent per dayMedium dose 
• < 7.5 mg prednisone equivalent per dayLow dose 
Daily screening 
for patients in 
medical surgical 
floors on high 
dose 
corticosteroids 
Patient profiles 
reviewed for POC 
BG monitoring
(If none, RPh
recommended 
addition)
When two 
consecutive POC 
BG levels > 180 
mg/dL, 
pharmacist 
intervened to 
initiate or adjust 
insulin therapy
Primary Outcomes Phase I (n=50) Phase II (n=49) P value
Incidence of routine POC BG monitoring, n (%)
DM, n (%)
Non-DM, n (%) 
POC BG levels, average (range)
18 (36)
15/17 (88)
3/33 (9)
206 (48-452)
43 (88)
14/14 (100)
29/35 (83)
182 (31-463)
p <0.05
--
--
NS
POC-confirmed incidence of hyperglycemia (%)
Unable to assess glycemic status, days 
134/180 (74)
208/388 (54)
150/282 (53)
127/409 (31)
p <0.05
--
Secondary Outcomes: Interventions Phase II (n=49)
# of pharmacy interventions 
Accepted by physician, n (%)
48
38 (79%)
Types of interventions, n (%)
Addition of POC BG monitoring 
Initiate insulin therapy 
Insulin adjustment  
29 (60%)
14 (30%)
5 (10%)
Additional Observations Phase I (n=50) Phase II (n=49) P value
Insulin regimens used, n (%)
Correction scale only 
Basal-bolus + correction scale 
Basal insulin + correction scale 
18 (36)
4 (22)
7 (39)
7 (39)
34 (69)
21 (62)
10 (29)
3 (9)
p <0.05
--
--
--
Incidence of hypoglycemia (%) 10/878 (1.1) 13/1475 (0.9) NS
NS= not significant
Baseline Characteristics Phase I (n=50) Phase II (n=49) 
Average age, years 
Gender - female, n (%)
Diabetes mellitus (DM), n (%) 
70
26 (52)
17 (34)
70
34 (69)
14 (29)
Average duration of corticosteroid therapy, days 8 8
Indication, n (%)
• Pulmonary
• Inflammatory
• Other 
34 (68)
6 (12)
7 (14)
39 (80)
5 (10)
5 (10)
Risk Factors, n (%)
• Age > 65 years 
• BMI >25 kg/m2
• BMI > 30 kg/m2
• Diabetes
• eGFR <40 mL/min/1.73m2
• African American
29 (58)
33 (66)
15 (30)
17 (34)
8 (16)
6 (12)
33 (67)
26 (53)
21 (43)
14 (29)
7 (14)
10 (20)
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